{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T06:28:19Z","timestamp":1768544899396,"version":"3.49.0"},"posted":{"date-parts":[[2019,11,27]]},"group-title":"Neurology","reference-count":39,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2019,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Spinocerebellar ataxia type 3 (SCA3) is a devastating multisystemic neurodegenerative disease for which targeted molecular therapies are coming into reach (e.g. antisense oligonucleotides). To pave the way for upcoming translational trials, easily accessible biomarkers in SCA3 are needed, particularly for subjects at the preataxic stage and cross-validated also in animal models. We hypothesised that serum neurofilaments might serve as blood biomarkers of disease progression in both human SCA3 and mouse models, expecting increased concentrations already at the preataxic stage. Serum neurofilament light (NfL) and phosphorylated neurofilament heavy (pNfH) levels were determined by ultra-sensitive single molecule array (Simoa) in cross-sectional samples of ataxic and preataxic SCA3 subjects and controls in two independent cohorts (ESMI cohort = cohort #1: n=160, EuroSCA\/RiSCA cohort = cohort #2: n=89). Serum NfL and pNfH were also assessed in a 304Q SCA3 knock-in mouse model across presymptomatic and symptomatic disease stages (n=147). Ataxic SCA3 subjects showed increased serum NfL (p&lt;0.001) and pNfH (p&lt;0.001) levels in cohort #1, with NfL levels already increased in preataxic subjects (p&lt;0.001). All these results were replicated in cohort #2 (all p&lt;0.001). Cross-sectional NfL levels correlated with clinical disease severity (Scale for the Assessment and Rating of Ataxia [SARA]; r=0.43, p&lt;0.001) and with longitudinal disease progression (annual SARA score change, \u03f1=0.42, p=0.012). CAG count and age were significant predictors of individual NfL concentrations (each p&lt;0.001). NfL levels in preataxic subjects increased with proximity to individual expected onset of ataxia (p&lt;0.001), with significant elevations already 7.5 years before onset. Serum NfL and pNfH increases in SCA3 subjects were paralleled by similar changes in SCA3 knock-in mice, here also already starting at the presymptomatic stage and close to the onset of ataxin-3 protein increase. Serum concentrations of neurofilaments, particularly NfL, might provide easily accessible biomarkers of disease severity in both ataxic and preataxic SCA3 subjects and mice prior to conversion. Neurofilaments thus entail potential applications as progression, onset\/proximity and treatment-response markers in both human and murine SCA3 trials.<\/jats:p>","DOI":"10.1101\/19011882","type":"posted-content","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T14:45:14Z","timestamp":1574865914000},"source":"Crossref","is-referenced-by-count":1,"title":["Neurofilaments as blood biomarkers at the preataxic and ataxic stage of spinocerebellar ataxia type 3: a cross-species analysis in humans and mice"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-8597","authenticated-orcid":false,"given":"Carlo","family":"Wilke","sequence":"first","affiliation":[]},{"given":"Eva","family":"Haas","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-9228","authenticated-orcid":false,"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3265-0262","authenticated-orcid":false,"given":"Jennifer","family":"Faber","sequence":"additional","affiliation":[]},{"given":"Hector","family":"Garcia-Moreno","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4076-7516","authenticated-orcid":false,"given":"Magda M.","family":"Santana","sequence":"additional","affiliation":[]},{"given":"Bart","family":"van de Warrenburg","sequence":"additional","affiliation":[]},{"given":"Holger","family":"Hengel","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-3273","authenticated-orcid":false,"given":"Manuela","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Alessandro","family":"Filla","sequence":"additional","affiliation":[]},{"given":"Alexandra","family":"Durr","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2368-1182","authenticated-orcid":false,"given":"Bela","family":"Melegh","sequence":"additional","affiliation":[]},{"given":"Marcella","family":"Masciullo","sequence":"additional","affiliation":[]},{"given":"Jon","family":"Infante","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3508-4788","authenticated-orcid":false,"given":"Paola","family":"Giunti","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Neumann","sequence":"additional","affiliation":[]},{"given":"Jeroen","family":"de Vries","sequence":"additional","affiliation":[]},{"given":"Luis Pereira","family":"de Almeida","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Rakowicz","sequence":"additional","affiliation":[]},{"given":"Heike","family":"Jacobi","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7781-2766","authenticated-orcid":false,"given":"Rebecca","family":"Sch\u00fcle","sequence":"additional","affiliation":[]},{"given":"Stephan A.","family":"Kaeser","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Klockgether","sequence":"additional","affiliation":[]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[]},{"name":"SCA3 neurofilament study group","sequence":"additional","affiliation":[]},{"name":"European Integrated Project on Spinocerebellar Ataxias (EuroSCA\/RiSCA)","sequence":"additional","affiliation":[]},{"name":"European Spinocerebellar Ataxia Type 3\/Machado-Joseph Disease Initiative (ESMI)","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Barro","sequence":"additional","affiliation":[]},{"given":"Jeannette","family":"H\u00fcbener-Schmid","sequence":"additional","affiliation":[]},{"given":"Matthis","family":"Synofzik","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"issue":"8","key":"2020102912050960000_19011882v1.1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1474-4422(17)30124-2","article-title":"Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington\u2019s disease: a retrospective cohort analysis","volume":"16","year":"2017","journal-title":"Lancet neurology"},{"key":"2020102912050960000_19011882v1.2","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.110.117002"},{"key":"2020102912050960000_19011882v1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.11.006"},{"issue":"15 Supplement","key":"2020102912050960000_19011882v1.4","first-page":"S25.001","article-title":"Nusinersen in Infants Who Initiate Treatment in a Presymptomatic Stage of Spinal Muscular Atrophy (SMA): Interim Efficacy and Safety Results From the Phase 2 NURTURE Study (S25.001)","volume":"92","year":"2019","journal-title":"Neurology"},{"issue":"12","key":"2020102912050960000_19011882v1.5","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1474-4422(19)30354-0","article-title":"Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study","volume":"18","year":"2019","journal-title":"The Lancet Neurology"},{"key":"2020102912050960000_19011882v1.6"},{"key":"2020102912050960000_19011882v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00202-1"},{"key":"2020102912050960000_19011882v1.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70104-2"},{"key":"2020102912050960000_19011882v1.9","doi-asserted-by":"crossref","unstructured":"Khalil M , Teunissen CE , Otto M , Piehl F , Sormani MP , Gattringer T , et al. Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology 2018.","DOI":"10.1038\/s41582-018-0058-z"},{"key":"2020102912050960000_19011882v1.10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-3-319-71779-1_11","article-title":"The Neuropathology of Spinocerebellar Ataxia Type 3\/Machado-Joseph Disease","volume":"1049","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"2020102912050960000_19011882v1.11","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","year":"2016","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2020102912050960000_19011882v1.12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13024-019-0338-0","article-title":"Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3","volume":"14","year":"2019","journal-title":"Molecular Neurodegeneration"},{"key":"2020102912050960000_19011882v1.13","unstructured":"Martier R , Gonzalez MS , Stricker-Shaver J , H\u00fcbener-Schmid J , Keskin S , Klima J , et al. Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease. Molecular Therapy - Methods & Clinical Development."},{"key":"2020102912050960000_19011882v1.14","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25264"},{"issue":"7","key":"2020102912050960000_19011882v1.15","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/acn3.212","article-title":"CSF neurofilament light chain reflects corticospinal tract degeneration in ALS","volume":"2","year":"2015","journal-title":"Annals of clinical and translational neurology"},{"issue":"4","key":"2020102912050960000_19011882v1.16","doi-asserted-by":"crossref","first-page":"e62043","DOI":"10.1371\/journal.pone.0062043","article-title":"Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice","volume":"8","year":"2013","journal-title":"PLoS One"},{"key":"2020102912050960000_19011882v1.17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/B978-0-444-51892-7.00027-9","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3","volume":"103","year":"2012","journal-title":"Handbook of clinical neurology"},{"key":"2020102912050960000_19011882v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.92"},{"key":"2020102912050960000_19011882v1.19","first-page":"1167","article-title":"Diagnostic and Prognostic Performance of Neurofilaments in ALS","volume":"9","year":"2018","journal-title":"Frontiers in neurology"},{"issue":"2","key":"2020102912050960000_19011882v1.20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","article-title":"Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease","volume":"25","year":"2019","journal-title":"Nat Med"},{"key":"2020102912050960000_19011882v1.21","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx224"},{"key":"2020102912050960000_19011882v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2013.01.001"},{"key":"2020102912050960000_19011882v1.23","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000219042.60538.92"},{"key":"2020102912050960000_19011882v1.24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001015"},{"key":"2020102912050960000_19011882v1.25","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2013-102200"},{"key":"2020102912050960000_19011882v1.26","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx039"},{"key":"2020102912050960000_19011882v1.27","doi-asserted-by":"crossref","unstructured":"Weish\u00e4upl D , Schneider J , Peixoto Pinheiro B , Ruess C , Dold SM , von Zweydorf F , et al. Physiological and pathophysiological characteristics of ataxin-3 isoforms. J Biol Chem 2018.","DOI":"10.1074\/jbc.RA118.005801"},{"key":"2020102912050960000_19011882v1.28","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24552"},{"issue":"7","key":"2020102912050960000_19011882v1.29","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s00415-018-8893-9","article-title":"Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study","volume":"265","year":"2018","journal-title":"J Neurol"},{"key":"2020102912050960000_19011882v1.30","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312972"},{"key":"2020102912050960000_19011882v1.31","doi-asserted-by":"crossref","unstructured":"Wilke C , Pujol-Calder\u00f3n F , Barro C , Stransky E , Blennow K , Michalak Z , et al. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clinical Chemistry and Laboratory Medicine (CCLM); 2019.","DOI":"10.1515\/cclm-2019-0015"},{"key":"2020102912050960000_19011882v1.32","doi-asserted-by":"crossref","unstructured":"Winter B , Guenther R , Ludolph AC , Hermann A , Otto M , Wurster CD . Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. J Neurol Neurosurg Psychiatry 2019.","DOI":"10.1136\/jnnp-2018-320033"},{"issue":"6","key":"2020102912050960000_19011882v1.33","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis","volume":"81","year":"2017","journal-title":"Ann Neurol"},{"key":"2020102912050960000_19011882v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00202-1"},{"key":"2020102912050960000_19011882v1.35","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-3-319-71779-1_11","article-title":"The Neuropathology of Spinocerebellar Ataxia Type 3\/Machado-Joseph Disease","volume":"1049","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"2020102912050960000_19011882v1.36","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1515\/cclm-2015-1195","article-title":"Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa","volume":"54","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2020102912050960000_19011882v1.37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/B978-0-444-51892-7.00027-9","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3","volume":"103","year":"2012","journal-title":"Handbook of clinical neurology"},{"key":"2020102912050960000_19011882v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2017.92"},{"key":"2020102912050960000_19011882v1.39","doi-asserted-by":"crossref","unstructured":"Wilke C , Pujol-Calder\u00f3n F , Barro C , Stransky E , Blennow K , Michalak Z , et al. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clinical Chemistry and Laboratory Medicine (CCLM); 2019.","DOI":"10.1515\/cclm-2019-0015"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/19011882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:32:44Z","timestamp":1768483964000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/19011882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,27]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1101\/19011882","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.15252\/emmm.201911803","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2019,11,27]]},"subtype":"preprint"}}